# Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

> **NCT07036003** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dr. David Wasserstein** · enrollment: 34 (estimated)

## Conditions studied

- Knee Osteoarthritis (Knee OA)
- Knee Osteoarthritis (OA)

## Interventions

- **DRUG:** Somatropin (recombinant human growth hormone)
- **DRUG:** bacteriostatic saline placebo

## Key facts

- **NCT ID:** NCT07036003
- **Lead sponsor:** Dr. David Wasserstein
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-31
- **Primary completion:** 2028-07
- **Final completion:** 2029-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07036003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07036003, "Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07036003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*